GRI GRI Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1824293 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY30.6%
TTM EPS YoY101.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-144.6%
ROA-107.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets9.8%
Debt / equity0.00x
Current ratio10.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.23x
Accruals ratio24.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $212,000 | $407,000 | $361,000 | $1.63M | $1.77M | $1.88M | $1.64M | $829,000 |
| SG&A expense | $1.30M | $1.24M | $1.64M | $1.03M | $1.60M | $1.02M | $1.41M | $1.12M |
| Operating income | -$1.51M | -$1.65M | -$2.00M | -$2.66M | -$3.37M | -$2.90M | -$3.05M | -$1.95M |
| Net income | -$1.51M | -$1.64M | -$2.00M | -$2.66M | -$3.36M | -$2.89M | -$3.05M | -$1.95M |
| EBITDA | -$1.51M | -$1.65M | -$2.00M | -$2.66M | -$3.36M | -$2.90M | -$3.05M | -$1.95M |
| EPS (basic) | -0.69 | -0.91 | -1.61 | — | -35.88 | -36.72 | -162.30 | — |
| EPS (diluted) | -0.69 | -0.91 | -1.61 | — | -35.88 | -36.72 | -162.30 | — |
| Weighted avg. shares (diluted) | 2.19M | 1.80M | 1.24M | — | 93,627 | 78,757 | 18,768 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $9.47M | $10.95M | $11.05M | $8.23M | $4.05M | $5.12M | $3.28M | $5.03M |
| Current assets | $9.73M | $11.33M | $11.28M | $8.59M | $4.70M | $5.58M | $3.93M | $5.62M |
| PP&E, net | $2,000 | $2,000 | $2,000 | $3,000 | $1,000 | $2,000 | $3,000 | $4,000 |
| Total assets | $9.76M | $11.38M | $11.34M | $8.67M | $4.78M | $5.67M | $4.04M | $5.74M |
| Current liabilities | $953,000 | $1.10M | $794,000 | $2.64M | $2.76M | $2.31M | $2.78M | $1.64M |
| Total liabilities | $953,000 | $1.10M | $794,000 | $2.66M | $2.79M | $2.35M | $2.84M | $1.71M |
| Shareholders' equity | $8.81M | $10.28M | $10.54M | $6.01M | $1.99M | $3.32M | $1.21M | $4.03M |
| Shares outstanding | 2.19M | 2.19M | 1.58M | 497,693 | 3.27M | 2.50M | 525,358 | 18,768 |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.48M | -$1.45M | -$3.69M | -$2.97M | -$2.31M | -$3.17M | -$1.74M | -$2.00M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.00M |
| Investing cash flow | — | — | — | — | — | — | — | $0 |
| Financing cash flow | $0 | $1.34M | $6.50M | $7.15M | $1.25M | $5.01M | -$11,000 | $2.28M |
| Depreciation & amortization | $0 | $0 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Stock-based compensation | $33,000 | $34,000 | $31,000 | $67,000 | $465,000 | $41,000 | $220,000 | $37,000 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.